PETACH TIKVA, Israel, July 12, 2019 (Newswire.com) – OrSense Ltd., a leading developer of systems for non-invasive measurements of hemoglobin, today announces the selection of its NBM-200 non-invasive Hemoglobin measurement device by the Banc de Sang I Teixits, the central blood bank of Catalonia….

Read more

Petach Tikva, Israel, May 14, 2019 (Newswire.com) – OrSense Ltd., a leading developer of systems for non-invasive measurements of Hemoglobin, today announces that its NBM200 non-invasive Hemoglobin measurement device has received FDA/CBER 510(K) clearance for use in blood banks…

Read more

OrSense re-awarded the Catalan blood bank contract for pre-donation Hemoglobin testing

Petach Tikva, Israel, August 5, 2015 – OrSense Ltd., a leading developer of systems for non-invasive measurements of Hemoglobin, announces a new 2-years contract to provide non-invasive pre-donation Hemoglobin testing systems to Banc De Sang I Teixits, the central blood bank of Catalonia following a competitive public tender.

Banc De Sang was one of the first major blood banks in Europe to move from capillary to non-invasive pre-donation Hb testing back in 2013, selecting the NBM-200 as its preferred testing system. More than half a million donors were tested since then by the NBM-200 systems operating in all branches and mobile units throughout Catalonia. The award follows an evaluation of multiple competing systems.  

Non invasive Hemoglobin testing uses optical measurement to replace traditional invasive blood testing. The NBM200 offers accurate, painless, Hb measurements on location. The non-invasive test further reduces infection risk as no blood is drawn, and with no consumables such as lancets, gloves etc. and no need for hazardous waste handling the system is also environmentally friendly.

“We are happy and proud of this contract win” said Yoav Reisman, CEO of OrSense. “Winning any competitive tender is a challenge. Winning a repeat contract from a large, experienced, active user such as Banc De Sang is also an important vote of confidence – in the principle of non-invasive testing in general and in OrSense technology in particular”

About OrSense 
OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurement of Hemoglobin. OrSense’s systems are available and been successfully installed in dozens of blood donation facilities worldwide. OrSense’s products are based on its proprietary Occlusion Spectroscopy technology. For additional information, please visit OrSense’s website at www.orsense.com.

About The Banc De Sang I Teixits

The Banc de Sang i Teixits (Blood and Tissue Bank, BST) is a public agency of the Catalan Department of Health whose mission is to guarantee the supply and proper use of human blood and tissue in Catalonia. It is also a leading center in the field of immunodiagnostics and advanced therapy development.

Orsense Ltd. contact:

Guy Greitser

OrSense Ltd.

Tel:  +972-3-7404911

E-mail: guy.greitser@orsense.com

OrSense delivers first systems in Mexico

Petach Tikva, Israel, October 28, 2014 – OrSense Ltd., developer of solutions for non-invasive measurements of hemoglobin, today announces a first delivery of its NBM200 non-invasive Hemoglobin testing systems in Mexico.

The delivery of systems comes after a successful evaluation of the NBM200 by Falcón, OrSense’s distributor to Mexico and Banco Central de Sangre CMN La Raza, one of the largest blood collection centers in Mexico. Mexico is the second major market in Latin America embracing the NBM-200 in the last 6 months, following the commencement of distribution in Brazil.

Non invasive Hemoglobin testing uses optical measurement to replace traditional invasive blood testing. The NBM200 offers accurate, painless, Hb measurements on location. The non-invasive test further reduces infection risk as no blood is drawn, and with no consumables such as lancets, gloves etc. and no need for hazardous waste handling the system is also environmentally friendly.

Commented Yoav Reisman, CEO of Orsense: “The NBM200 is the most common Non invasive Hb screening product in blood banks today, in use by dozens of operators around the world. We introduced it in Brazil a few months ago and are pleased to have it now launched to the Mexican market. We are working closely with Falcón and are confident that users in Mexico will appreciate the benefits that others are already enjoying”.

About OrSense 
OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurement of Hemoglobin. OrSense’s systems are available and been successfully installed in dozens of blood donation facilities worldwide. OrSense’s products are based on its proprietary Occlusion Spectroscopy technology. For additional information, please visit OrSense’s website at www.orsense.com.

About Falcon

Instrumentos y equipos Falcón is a market leading distributor of medical equipment to the Mexican market. Founded in 1979 Falcon provides a broad range of services including marketing, distribution, sale and technical support of equipment and reagents for clinical diagnosis, blood banks, tomography, imaging, industrial  and bioresearch. For additional information, please visit Falcón’s website at www.falconmx.com.

About OrSense’s Technology

OrSense’s NBM200 is based on the company’s proprietary SpectOLight^TM technology, which uses an optical measurement platform combined with a ring-shaped sensor that is fitted on the subject’s finger.  A gentle pressure is applied by the sensor, temporarily occluding the blood flow in the finger. New blood dynamics are created, generating a unique, strong optical transmission signal, with a high signal-to-noise ratio which is wholly blood specific. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the subject’s blood constituents.

Orsense Ltd. contact:

Mikael Flensburg

Chief Commercial Officer

OrSense Ltd.

Mobile: +46 (0) 760 477090

E-mail: mikael.flensburg@orsense.com

Petach Tikva, Israel, October 14, 2014 – OrSense Ltd., developer of solutions for non-invasive measurements of hemoglobin, today announced that CSL Plasma, Germany, has completed the transition to OrSense’s NBM200 Hb testing device for screening of Hb levels in plasma donors.

CSL Plasma is one of the world’s largest plasma collection organizations, operating collection centers across the United States and Germany.

Deployment of the NBM200 systems in all collection centers in Germany started earlier this summer after a thorough evaluation and has now been completed.

Historically, Hb measurement required collection of blood samples, rendering the testing procedures invasive, painful, time consuming and labor intensive. OrSense’s NBM200 offers a non-invasive solution for accurate Hb measurements that eliminates pain, reduces infection risk and enables swift Hb level analysis. The NBM200 solution is also environmentally friendly, as it requires no consumables such as lancets, gloves etc., and no need for hazardous waste handling.

Commented Yoav Reisman, CEO of Orsense: “We are happy and proud of CSL’s selection of the NBM200. CSL was looking to improve donors’ experience and streamline operations and the NBM200 provided both. The NBM200 is the most common Non invasive Hb screening product in blood banks today, in use by dozens of operators around the world and this entry into the world of international plasma collection organizations is a natural expansion”.

About OrSense 
OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurement of Hemoglobin, based on its proprietary Occlusion Spectroscopy technology. OrSense’s systems are available and been successfully installed in dozens of blood donation facilities worldwide. For additional information, please visit OrSense’s website at www.orsense.com.

About OrSense’s Technology

OrSense’s NBM200 is based on the company’s proprietary SpectOLight^TM technology, which uses an optical measurement platform combined with a ring-shaped sensor that is fitted on the subject’s finger.  A gentle pressure is applied by the sensor, temporarily occluding the blood flow in the finger. New blood dynamics are created, generating a unique, strong optical transmission signal, with a high signal-to-noise ratio which is wholly blood specific. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the subject’s blood constituents.

Orsense Ltd. contact:

Mikael Flensburg

Chief Commercial Officer

OrSense Ltd.

Mobile: +46 (0) 760 477090

E-mail: mikael.flensburg@orsense.com

Petach Tikva, Israel, July 15, 2014 – OrSense Ltd., developer of solutions for non-invasive measurements of hemoglobin, today announces a first delivery of its NBM200 non-invasive Hemoglobin testing systems in Brazil.

The delivery of systems follows the recent approval of the NBM200 by Anvisa, the Brazilian Health Surveillance Agency. The NBM200 systems will be distributed and serviced in Brazil by Fujicom, a national distributor of medical equipment and supplies to hospitals and blood banks.

Non invasive Hemoglobin testing uses optical measurement to replace traditional invasive blood testing. The NBM200 offers accurate, painless, Hb measurements on location. The non-invasive test further reduces infection risk as no blood is drawn, and with no consumables such as lancets, gloves etc. and no need for hazardous waste handling the system is also environmentally friendly.

Commented Yoav Reisman, CEO of Orsense: “We are happy to add Brazil to the growing list of countries were the NBM 200 has now been cleared and being put to use, and Fujicom as a business partner”.  Edmar Fujita Jr CEO of Fujicom, Orense’s distributor in Brazil said “We have been preparing for the NBM200 launch for some time and now with the Anvisa approval in place expect to move ahead quickly to introduce the systems to our clients“

About OrSense 

OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurement of Hemoglobin. OrSense’s systems are available and been successfully installed in dozens of blood donation facilities worldwide. OrSense’s products are based on its proprietary Occlusion Spectroscopy technology. Investors in the Company include Israel Health Care Ventures, Saints Capital and LTG. For additional information, please visit OrSense’s website at www.orsense.com.

About Fujicom

Fujicom is a national distributor of medical equipment and supplies to hospitals and blood banks. Fujicom was established in 1998 and is part of the Fujita group. For additional information, please visit Fujicom’s website at www.fujicom.com.br

About OrSense’s Technology

OrSense’s NBM200 is based on the company’s proprietary SpectOLightTM technology, which uses an optical measurement platform combined with a ring-shaped sensor that is fitted on the subject’s finger.  A gentle pressure is applied by the sensor, temporarily occluding the blood flow in the finger. New blood dynamics are created, generating a unique, strong optical transmission signal, with a high signal-to-noise ratio which is wholly blood specific. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the subject’s blood constituents.

* * *

Orsense Ltd. contact:
Mikael Flensburg
Chief Commercial Officer
OrSense Ltd.
Mobile: +46 (0) 760 477090
E-mail: mikael.flensburg@orsense.com

Petach Tikva, Israel, May 30, 2014 – OrSense Ltd., developer of solutions for non-invasive measurements of hemoglobin, today announced that Haema AG, Germany, has completed the transition to OrSense’s NBM200 Hb testing device for screening of Hb levels in blood donors. Haema is the largest privately operated blood bank in Germany and one of the largest in the world, performing over 1.1 million Hb tests per year in 33 blood donation centers across Germany. Haema selected OrSense’s NBM200 after rigorous testing in multiple locations. Deployment of the NBM200 systems started in January 2014 and been completed earlier this month.

Historically, Hb measurement required collection of blood samples, rendering testing procedures invasive, painful, time consuming and labor intensive. OrSense’s NBM200 offers a non-invasive solution for accurate Hb measurements that eliminates pain, reduces infection risk and enables swift Hb level analysis. The NBM200 solution is also environmentally friendly, as it requires no consumables such as lancets, gloves etc, and no need for hazardous waste handling.  

Commented Yoav Reisman, CEO of Orsense: “The NBM200 is already in use by dozens of operators around the world. We are very pleased with the acceptance of it by such a world class operator, which we hold as a further vote of confidence in the non-invasive testing approach in general and OrSense’s unique solution in particular”

About OrSense 

OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurement of Hemoglobin. OrSense’s systems are available and been successfully installed in dozens of blood donation facilities worldwide. OrSense’s products are based on its proprietary Occlusion Spectroscopy technology. Investors in the Company include Israel Health Care Ventures, Saints Capital and LTG. For additional information, please visit OrSense’s website at www.orsense.com.

About OrSense’s Technology

OrSense’s NBM200 is based on the company’s proprietary SpectOLight^TM technology, which uses an optical measurement platform combined with a ring-shaped sensor that is fitted on the subject’s finger.  A gentle pressure is applied by the sensor, temporarily occluding the blood flow in the finger. New blood dynamics are created, generating a unique, strong optical transmission signal, with a high signal-to-noise ratio which is wholly blood specific. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the subject’s blood constituents.

* * *

Orsense Ltd. contact:

Mikael Flensburg

Chief Commercial Officer

OrSense Ltd.

Mobile: +46 (0) 760 477090

E-mail: mikael.flensburg@orsense.com

Petach Tikva, Israel, November 5, 2013 – OrSense Ltd., developer of solutions for non-invasive measurements of various blood parameters, today announced that it has received FDA clearance for its NBM-200MP, noninvasive hemoglobin (Hb) and pulse oximetry monitor. NBM-200MP belongs to OrSense’s NBM-200 family of products, for the noninvasive measurement of Hb levels, enabling monitoring of anemia and hemorrhage.

Currently, Hb measurements require collection of blood samples, rendering   existing testing methods invasive, painful, time consuming and labor intensive. OrSense’s systems offer a unique, breakthrough, non-invasive solution for accurate Hb measurements and hold the potential for improving anemia detection and monitoring by eliminating pain, reducing infection risk and enabling swift Hb level analysis. In addition, noninvasive Hb monitoring offers, for the first time, the possibility of continuous Hb measurement, which can be critical when monitoring bleeding in acute conditions, such as during surgery or childbirth. The NBM-200 systems are compatible with a variety of clinical environments, including hospitals, outpatient clinics and mobile health, and are used for various applications such as primary care, public screening, women health and homecare.

“Hemoglobin levels are a critical parameter in practically every aspect of medical care – in the chronically ill, women’s health, during child development, in the operating room and intensive care wards, and during routine checkups in outpatient clinics. Although over 400 million Hb lab tests are performed annually in the U.S. alone, this important blood test remains costly, time consuming, invasive and intermittent,” said Lior Maayan, CEO of OrSense. “Our noninvasive hemoglobin monitor offers a true revolution in the management of both acute and chronic anemia. We are very excited that soon after receiving China FDA approval and in addition to the CE Mark, our hemoglobin and oximetry monitor has now received regulatory recognition in the U.S., which marks the first and important step towards bringing OrSense’s solution to the U.S. market for the benefit of patients in the U.S. and worldwide.”

About OrSense’s Technology

OrSense’s devices are based on its proprietary SpectOLight^TM technology, which uses an optical measurement platform combined with a ring-shaped sensor that is fitted on the subject’s finger.  A gentle pressure is applied by the sensor, temporarily occluding the blood flow in the finger. New blood dynamics are created, generating a unique, strong optical transmission signal, with a high signal-to-noise ratio which is wholly blood specific. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the subject’s blood constituents.

About Anemia

Anemia is a condition in which there are not enough healthy red blood cells, and therefore not enough Hb to carry adequate oxygen to the tissues. Anemia is diagnosed when Hb levels are lower than normal. This condition affects close to 2 billion people worldwide and is crucial in maternal health, infectious diseases and nutrition. Yet, despite its prevalence, it remains one the most underdiagnosed conditions in community healthcare. Anemia is highly prevalent in the U.S., with an estimated 15% of young children,10% of women and the elderly, up to 75% of people undergoing surgery and 90% of in-patients suffering from low Hb levels. The long term effects of chronic anemia can be potentially serious, starting from poor development and reaching cardiovascular diseases. In addition, anemia is a key co-morbidity in noncommunicable diseases such as diabetes, cardiovascular diseases, cancer and respiratory conditions, and thus plays a key role in chronic disease management.

About OrSense 

OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense’s FDA cleared and CE approved noninvasive hemoglobin systems are available in 60 countries worldwide, and have been successfully installed in multiple environments including hospitals, physician offices, blood donation facilities, as well as used for various applications including public screening, women health, mobile health and homecare. OrSense’s products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. Investors in the Company include Israel Health Care Ventures, Saints Capital and LTG. For additional information, please visit OrSense’s website at www.orsense.com.

Press Contact:

Tsipi Haitovsky
Media Liaison
OrSense Ltd.
Tel: +972-52-598-9892
Email: tsipi.haitovsky@orsense.com

– The device will be launched at the China International Medical Equipment Fair –

Petach Tikva, Israel, October 28, 2013 – OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, today announced that it has received China Food and Drug Administration approval for NBM-200, its non-invasive hemoglobin (Hb) system for anemia monitoring and hemorrhage detection. The device will be launched in China at The 70^th China International Medical Equipment Fair that will take place on Nov. 3-6, 2013 in Siming District, Xiamen, Fujian, China.

Lior Maayan, CEO of OrSense said, “We are very excited that NBM-200, our non-invasive hemoglobin device, has been officially certified by the China Food and Drug Administration. The World Health Organization estimates that over 200 million people in China suffer from  anemia. China, with its healthcare reform and focus on primary care and prevention, represents a significant growth opportunity for our innovative platform. We believe that NBM-200 will be a welcome addition in hospitals, clinics, public health programs, blood donation centers and nutrition programs throughout China, due to its ease of use and safety profile, helping improve health in China as well as around the globe.”

Hemoglobin (Hb) measurements allow the detection of anemia and hemorrhage, and are widely used by hospital wards such as operating rooms, ICU, emergency and delivery rooms as well as in outpatient clinics and women and children healthcare facilities. In blood donation centers, a pre-donation Hb measurement is required from blood donors to protect anemic donors and to ensure adequate Hb content of blood units. Currently determination of Hb levels is usually performed using capillary blood obtained by finger pricking, rendering current Hb screening methods invasive, painful, time consuming and labor intensive.

Non-invasive measurement of Hb has many advantages, including the prevention of pain and potential transmission of infectious diseases and the reduced need for trained personnel. NBM-200 offers a unique, breakthrough, non-invasive solution for accurate and quick Hb measurements. Multiple trials, published reports, and registries of patients diagnosed with the NBM-200 device consistently demonstrate accurate measurements combined with a positive safety profile, reduction of infection risk and a greatly improved donor and patient comfort.

About NBM-200

OrSense’s portable non-invasive device or the measurement of Hb and oximetry operates via a ring-shaped sensor that is fitted on the person’s finger and applies pressure, temporarily occluding local blood flow. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the donor’s and patient’s blood constituents.

About OrSense 

OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense’s CE approved non-invasive hemoglobin monitor is available in 55 countries world-wide, and has been successfully installed in multiple environments including hospitals, physician offices, blood donation facilities, as well as used for various applications including public screening, women health and homecare. In addition, the Company’s FDA cleared NBM 200MP is a non-invasive blood oximetry monitor for use in hospitals. OrSense’s products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. For additional information, please visit OrSense’s website at www.orsense.com.

OrSense Non Invasive Hemoglobin Monitor Shown Safe and Accurate for Pre-Donation Screening in Blood Banks – Four abstracts demonstrating the clinical value of NBM-200 to be presented at the ISBT in Amsterdam – Petach Tikva, Israel, May 28, 2013 – OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced today that its non-invasive Hemoglobin (Hb) NBM-200 monitor was the topic of multiple recent studies highlighting the clinical value of the device. Four studies, from various countries around the world, were accepted for poster presentations at the International Society Blood Transfusion (ISBT) 2013 conference held in Amsterdam. All studies assessed NBM-200 as a pre-donation anemia screening device in blood banks, to prevent donations by people with Hb levels under the required cutoff. All four studies show that OrSense’s non-invasive NBM-200 Hb monitor is accurate, easy to use and favorably accepted by both staff and subjects. The studies were conducted independently by groups from Central Military Hospital – Military University Hospital Prague, Czech Republic; the Immunohematology and Transfusion Service, Policlinico S.Orsola-Malpighi, Bologna, Italy; Haema AG Leipzig, Germany; Assaf Harofe Hospital, Israel; Rabin Medical Center, Israel, and OrSense. The NBM-200 device was compared to standard venous laboratory tests and capillary point-of-care devices for Hb measurement, and the studies conclude that OrSense’s device is comparable to invasive, point-of-care Hb monitoring solutions while reducing risk of infection and eliminating the need for painful finger pricking. According to the study presented by Dr. Milos Bohonek, from the Military University Hospital Prague, OrSense’s monitor provides even better results than point-of-care capillary devices. In addition, the accuracy of NBM-200 is independent of age, gender and body temperature of healthy volunteers. The authors conclude that NBM-200 is suitable for pre-donation screening of blood donors, and is more comfortable for donors and safer for staff. The three other studies reach similar conclusions. Lior Maayan, CEO of OrSense said, “Numerous blood donation centers worldwide are successfully using our hemoglobin monitoring system and benefiting from its multiple advantages. Pre-donation hemoglobin and anemia screening is a routine and fundamental test aimed at protecting the health of potential blood donors. It is therefore imperative to be able to screen donors for anemia safely, quickly and reliably. Over the past two years, more than 25 studies performed on thousands of patients and donors demonstrate that NBM-200 not only offers this possibility but also eliminates the need for painful finger pricking as well as biologically hazardous equipment and waste. In addition, these studies highlight the fact that our non-invasive device has the potential to increase first time and repeat blood donations.” “After evaluating OrSense’s novel technology we found that it is comparable, or even better, to other existing methods. OrSense’s non-invasive system has many benefits that are highly appreciated by blood donors,” said Miloš Bohoněk, Ph.D., Head of Department of Hematology, Biochemistry and Blood Transfusion, Central Military Hospital, Prague, Czech Republic. Non Invasive Hemoglobin Measurement OrSense’s non-invasive Hb measurement has many advantages including the prevention of pain and potential transmission of infectious diseases, a reduced need for trained personnel, short measurement time, and the absence of bio-hazardous waste. It offers a unique, breakthrough, non-invasive solution for accurate and quick Hb measurements. The portable, wireless device operates via rechargeable batteries using a ring-shaped sensor that is fitted on the donor’s finger and applies pressure, temporarily occluding local blood flow. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This technology, called SpectOLight™, provides a quick, accurate and painless measurement of the donor’s blood constituents, while greatly improving donors’ comfort, eliminating infection risk, and providing the medical staff with accurate readings and immediate results. The device has received CE and CDN approvals. It exhibits comparable accuracy to invasive point-of-care solutions while also demonstrating a strong safety profile, ease of use and substantial cost reduction. About OrSense OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense’s CE approved non-invasive hemoglobin monitor is available in 55 countries world-wide, and has been successfully installed in multiple environments including hospitals, physician offices, blood donation facilities, as well as used for various applications including public screening, women health and homecare. In addition, the Company’s FDA cleared NBM 200MP is a non-invasive blood oximetry monitor for use in hospitals. OrSense’s products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. For additional information, please visit OrSense’s website at www.orsense.com. Press Contact: Tsipi Haitovsky Media Liaison, OrSense Ltd. Tel: +972-52-598-9892 Email: tsipi.haitovsky@orsense.com

WE JUST MOVED:

As part of our natural growth, we moved to our new premises as of October 25, 2012
Our new contact details are as follows:

17 Ha’Mefalsim St.,
Kiryat Arie
POB 10383
Petah-Tikva 49003
Israel

Tel: +972.3.7404900
Fax: +972.3.7404909

email: info@orsense.com

– A body of publications, five of which at the AABB Annual Meeting, highlights the clinical value of OrSense’s system –

– Glasswing™, next-generation, wireless, non-invasive hemoglobin measurement system for anemia screening, to be launched at AABB –

Nes Ziona, Israel, October 4, 2012 – OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, reports today that its non-invasive Hemoglobin (Hb) monitor was the topic of multiple recent studies highlighting the clinical value of the device. Five studies, from various countries around the world, will be presented as posters at the AABB Annual Meeting & CTTXPO 2012, held at Boston on October 6-9, 2012, and two were presented in the DGTI Annual Congress held at Graz, Austria in September. In addition, two studies were recently published in the distinguished, peer-reviewed journals Transfusion and the Journal of Maternal-Fetal and Neonatal Medicine. All studies conclude that OrSense’s non-invasive Hb monitor is reliable, accurate, easy to use and favorably accepted by both staff and subjects.

The studies were conducted independently by groups from Central Institute for Blood Transfusion and Immunology, Innsbruck, Austria; State University of Campinas, Brazil; the Madrid Red Cross, Spain; Haema AG, Leipzig, and Deutsche Gesellschaft für Humanplasma Krefeld both from Germany; Korea Yonsei University and Hanmaum Blood Center; Assaf Harofe Hospital, Israel; and Rabin Medical Center, Israel. Most of the studies were conducted in order to assess OrSense’s non-invasive Hb monitor for pre-screening blood donors for anemia. The studies conclude that OrSense’s device is comparable to invasive, point-of-care Hb monitoring solutions in terms of accuracy and reliability, and is superior to invasive solutions since it reduces risk of infection and eliminates the need for painful finger pricking.

According to the study by the group of Dr. Vagner Castro from the University of Campinas, Brazil, published in Transfusion (Pinto et. al. July 2012) the results obtained suggest that the OrSense monitor is more precise than the prevalent invasive point-of-care device in preventing anemic donors from donating. In addition, the study performed by the Spanish group, led by Dr. Emma Castro, from the Spanish Red Cross Transfusion Center in Madrid, assessed for the first time the impact of the non-invasive Hb monitoring experience on both staff and subjects in a blood bank facility. The researchers suggested that “in our opinion, procuring a better experience for blood donors may undisputedly facilitate repetition.”

Lior Maayan, CEO of OrSense said, “Our revolutionary technology ushers diagnostics into a new era of non-invasive monitoring of various blood parameters. In particular, our non-invasive Hb monitor is unique in offering accurate, non-invasive measurements of this important parameter. Concerning blood banks, pre-donation Hb and anemia screening is vital for protecting the health of potential blood donors and is the most common reason for disqualifying donors. It is therefore imperative to be able to screen donors for anemia safely, quickly and reliably. The impressive body of work that was recently published regarding our non-invasive solution shows unequivocally that our device not only offers this possibility but also eliminates the need for painful finger pricking as well as biologically hazardous equipment and waste. In addition, these studies highlight the fact that our non-invasive device has the potential to increase first time and repeat blood donations.”

OrSense will launch Glasswing^TM, its next-generation, wireless, non-invasive hemoglobin (Hb) measurement system for anemia monitoring, hemorrhage detection and pre-donation , during the AABB meeting later this week.

Non Invasive Hemoglobin Measurement
OrSense’s non-invasive Hb measurement has many advantages including the prevention of pain and potential transmission of infectious diseases, a reduced need for trained personnel, short measurement time, and the absence of bio-hazardous waste. It offers a unique, breakthrough, non-invasive solution for accurate and quick Hb measurements. The portable, wireless device operates via rechargeable batteries using a ring-shaped sensor that is fitted on the donor’s finger and applies pressure, temporarily occluding local blood flow. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This technology, called SpectOLight™, provides a quick, accurate and painless measurement of the donor’s blood constituents, while greatly improving donors’ comfort, eliminating infection risk, and providing the medical staff with accurate readings and immediate results.

The device has received CE and CDN approvals. It was tested on over 8,000 patients and blood donors at 20 sites in the U.S., Europe and South Africa exhibiting comparable accuracy to invasive POC solutions while also demonstrating a strong safety profile, ease of use and substantial cost reduction. The system is based on OrSense’s proprietary SpectOLight™ technology, which uses a non-invasive optical measurement platform combined with a ring-shaped pneumatic probe that fits on the finger.

About Glasswing
In July 2012, OrSense introduced GlasswingTM, its next-generation, wireless, non-invasive Hb measurement system for anemia monitoring, hemorrhage detection and pre-donation screening. Glasswing offers a unique, breakthrough non-invasive solution for accurate continuous and spot Hb measurements. The new portable, wireless system enables on-line storage and download of data, real-time communication with electronic medical records in the hospital or blood donation centers as well as with other digital data devices and printers. The device is well suited for use in a variety of clinical environments, including perioperative and critical care, emergency medicine, blood donation facilities, women’s health, primary care physician’s office and homecare. GlasswingTM is pending FDA 510(k) clearance.

About OrSense
OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense’s CE approved non-invasive hemoglobin monitor is available in 55 countries world-wide, and has been successfully installed in multiple environments including hospitals, physician offices, blood donation facilities, as well as used for various applications including public screening, women health and homecare. In addition, the Company’s FDA cleared NBM 200MP is a non-invasive blood oximetry monitor for use in hospitals. OrSense’s products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. Investors in the Company include Israel Health Care Ventures and STAR Ventures. For additional information, please visit OrSense’s website at www.orsense.com.

Press Contact:
Tsipi Haitovsky
Media Liaison
OrSense Ltd.
Tel: +972-52-598-9892
Email: tsipi.haitovsky@orsense.com

Cancun, Mexico, July 9, 2012 – OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, introduced today at the 32nd International Congress of the International Society of Blood Transfusion (ISBT), in Cancun, Mexico, Glasswing^TM, its next-generation, wireless, non-invasive hemoglobin (Hb) measurement system for anemia monitoring, hemorrhage detection and pre-donation screening.

Hemoglobin (Hb) measurements allow the detection of anemia and hemorrhage, and are widely used in hospital wards such as operation rooms, ICU, ER and delivery rooms. In blood donation centers, a pre-donation Hb measurement of blood donors is required by most countries to protect anemic donors, and to ensure adequate Hb content of blood units. The determination of Hb levels of prospective blood donors is usually performed using capillary blood obtained by finger pricking, rendering current Hb screening methods invasive, painful, time consuming and labor intensive.

Glasswing, OrSesnes’s next-generation, wireless device offers a unique, breakthrough non-invasive solution for accurate continuous and spot Hb measurements. The new portable, wireless system enables on-line storage and download of data, real-time communication with electronic medical records in the hospital or blood donation centers as well as with other digital data devices and printers. The device is well suited for use in a variety of clinical environments, including perioperative and critical care, emergency medicine, blood donation facilities, women’s health, primary care physician’s office and homecare.

“We are proud to introduce Glasswing, our improved revolutionary solution for non-invasive measurements of hemoglobin,” said Lior D. Ma’ayan, CEO of OrSense. “OrSense’s non-invasive solution improves anemia screening and monitoring by eliminating pain, reducing infection risk and enabling a simple and fast diagnosis. Hemoglobin measurements obtained by our system in multiple applications, showed accurate performance compared with the gold standard invasive reference values. Our non-invasive system was found to be environmentally friendly, safe, fast and easy to use by the operating staff, and is already in use in multiple blood donation centers and blood banks in around the world, improving donor and patient safety and care.”

In addition, 2 poster presentations will be presented at ISBT, with results of clinical trials showing that Hb measurements obtained with OrSense’s systems showed accurate performance compared with invasive point of care (POC) devices. Dr. M. Gavalaki of the Blood Transfusion Center at Laiko General Hospital, Athens, Greece will present a poster titled Evaluation of non-invasive pre-donation hemoglobin screening; and Aharon Weinstein, Vice President of Research at OrSense will present a poster titled Non-invasive hemoglobin sensor performance in anemia screening.

For additional information, please visit OrSense’s new corporate website at www.orsense.com

Non Invasive Hemoglobin Measurement
OrSense’s non-invasive Hb measurement has many advantages including the prevention of pain and potential transmission of infectious diseases, a reduced need for trained personnel, short measurement time, and the absence of bio-hazardous waste. Glasswing offers a unique, breakthrough, non-invasive solution for accurate and quick Hb measurements. This portable, wireless device operates via rechargeable batteries using a ring-shaped sensor that is fitted on the donor’s finger and applies pressure, temporarily occluding local blood flow. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This technology, called SpectOLight™, provides a quick, accurate and painless measurement of the donor’s blood constituents, while greatly improving donors’ comfort, eliminating infection risk, and providing the medical staff with accurate readings and immediate results.

About OrSense
OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense’s CE approved non-invasive hemoglobin monitor is available in 55 countries world-wide, and has been successfully installed in multiple environments including hospitals, physician offices, blood donation facilities, as well as used for various applications including public screening, women health and homecare. In addition, the Company’s FDA cleared NBM 200MP is a non-invasive blood oximetry monitor for use in hospitals. OrSense’s products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. The Company’s CE approved glucose monitor was tested on over 450 diabetic subjects, showing performance similar to those of invasive glucose sensors. Investors in the Company include Israel Health Care Ventures and STAR Ventures. For additional information, please visit OrSense’s website at www.orsense.com.

Press Contact:
Tsipi Haitovsky
Media Liaison
OrSense Ltd.
Tel: +972-52-598-9892
Email: tsipi.haitovsky@orsense.com

Nes Ziona, Israel, June 14, 2012 – OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, introduced at the European Congress for Perinatal Medicine (ECPM), held in Paris, France at June 13-16, results of a successful clinical trial using NBM200, a non-invasive hemoglobin (Hb) measurement system for anemia screening and hemorrhage detection. Dr. Eran Hadar, of the Department of Maternal Fetal Medicine at Rabin Medical Center, Israel, presented results showing that OrSenes’s device was as accurate as invasive point of care (POC) devices in measuring Hb levels in pregnant women.

“The clinical trial shows that OrSense’s system is accurate and user friendly for determining Hb levels non-invasively,” said Professor Moshe Hod, Director, Maternal Fetal Division of the Women’s Hospital at Rabin Medical Center, Israel. “Pregnant women are a particularly vulnerable anemia risk group that will greatly benefit from the ability offered by OrSenes’s solution to immediately and routinely screen for anemia, as part of a regular physician checkup. However, non-invasive monitoring of Hb levels is invaluable for anemia screening and hemorrhage detection not only in hospitals and physician offices, but also in community clinics throughout the world and for home care.”

Over one billion people suffer from iron deficiency anemia worldwide. During pregnancy the need for iron increases and exposes the mother to a higher risk of anemia.  Anemia is a prime reason for maternal mortality and acts as a predisposition for low neonate birth weight. In addition, severe anemia may aggravate the negative effect of postpartum hemorrhage, and endanger the mother. It is estimated that 40% of maternal deaths are caused directly or indirectly by anemia.  

Reducing maternal mortality is one of the key global healthcare objectives. Close to 350,000 women die each year due to lack of proper diagnosis and treatment and several millions are effected. The inability to identify and treat anemia and hemorrhage in the developing world due to lack of infrastructure and personnel is a key limitation in the UN and WHO efforts to reduce maternal mortality.

OrSense has developed and commercialized a non-invasive, portable point of care (POC) monitoring system for measuring spot and continuous hemoglobin. The device offers, for the first time an accurate, safe, fast, easy to operate and affordable solution that would allow for anemia screening and monitoring. Being non invasive, it eliminates the need for finger prick and biochemistry based blood test, prevents infection risks and eliminates the need for handling bio-hazardous material. The continuous non-invasive hemoglobin functionality can serve for early detection of post partum hemorrhage and improved blood management post delivery. It has the potential of improving maternal health in the developed world by offering online needed information and eliminating safety risks while reducing cost of care. The system was tested on over 8,000 patients and blood donors at 20 sites in the U.S., Europe and South Africa exhibiting comparable accuracy to invasive POC solutions while also demonstrating a strong safety profile, ease of use and substantial cost reduction.

The product has received CE and CDN approvals and was submitted for FDA 510(k) clearance. The device is based on OrSense’s proprietary Occlusion Spectroscopy technology, which uses a non-invasive optical measurement platform combined with a ring-shaped pneumatic probe that fits on the finger.

About the clinical trial

OrSense system non-invasive Hemoglobin (Hb) system was tested by Dr. Eran Hadar, Dr. Kinneret Tennebaum and Dr. Tal Bouganim in the Women’s Hospital of Rabin Medical Center in Petah Tikva, Israel. Two non-invasive Hb measurements were performed on the right and left thumbs of the pregnant subject. Reference Hb values were obtained from venous blood samples and evaluated on a Beckman Coulter LH 750 counter, acting as reference “gold standard”.

A total of 126 data pairs were obtained in the trial from 63 pregnant women, and the values obtained by the device were in the range 7.7 – 14 g/dL. The mean error (bias) of the NBM200 readings comparing to the reference was 0.1 g/dL and the accuracy, defined as the standard deviation of error, was 0.86 g/dL. The correlation was 0.82 and the mean absolute error was 0.71 g/dL.

About OrSense

OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense’s CE approved non-invasive hemoglobin monitor is available in 40 countries world-wide, and has been successfully installed in multiple environments including hospitals, physician offices, blood donation facilities, as well as used for various applications including public screening, women health and homecare. In addition, the Company’s FDA cleared NBM 200MP is a non-invasive blood oximetry monitor for use in hospitals. OrSense’s s products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. The Company’s CE approved glucose monitor was tested on over 450 diabetic subjects, showing performance similar to those of invasive glucose sensors. Investors in the Company include Israel Health Care Ventures and STAR Ventures. For additional information, please visit OrSense’s corporate website at www.orsense.com.

Press Contact:

Tsipi Haitovsky

Media Liaison

OrSense Ltd.

Tel: +972-52-598-9892

Email: tsipi.haitovsky@orsense.com

Nes Ziona, Israel, October 20, 2011 – OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced today that 3 poster presentations on the clinical value of its NBM 200 non-invasive hemoglobin (Hb) monitor for pre-donation screening of anemia will be presented at the AABB Annual Meeting & CTTXPO 2011, in San Diego, California, to be held on October 22-25, 2011. The findings indicate that Hb measurements using OrSense’s NBM 200 are as accurate as measurements with currently available invasive devices. In addition, non-invasive measurements hold major advantages over current screening methods, such as the prevention of pain and potential transmission of infectious diseases to donors and caregivers, and the reduced need for trained personnel.

The following poster presentations will be presented:

Comparison Among a New Non-Invasive Hemoglobin Measurement System, Capillary Blood Azidemetahemoglobin Test and Red Blood Cell Count for Pre-Donation Screening. Belardinelli et al. Immunohematology and Transfusion Medicine, S.Orsola-Malpighi Hospital, Bologna, Italy.

Evaluation of a New Non-Invasive Hemoglobin Monitor as a Pre-Donation Application. Castro et al. Centro de Transfusión de Cruz Roja Española en Madrid, Spain.

Evaluation of a Non-Invasive Hemoglobin Estimation Method for Pre-Donation Screening in Blood Donors at a Tertiary Care Hospital Blood Bank in India – Verma; Dept. of Transfusion Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI), Lucknow, India.

About OrSense’s NBM 200 Non-Invasive Hemoglobin Screening System

Hemoglobin (Hb) measurements allow the detection of anemia and hemorrhage, and are widely used by hospital wards such as operating rooms, ICU, emergency and delivery rooms as well as in outpatient clinics and women’s and children’s health care facilities. In blood donation centers, a pre-donation Hb measurement of blood donors is required by most countries to protect anemic donors, and to ensure adequate Hb content of blood units. The determination of Hb levels of prospective blood donors is usually performed using capillary blood obtained by finger pricking, rendering current Hb screening methods invasive, painful, time consuming and labor intensive. Non-invasive measurement of Hb has many advantages including the prevention of pain and potential transmission of infectious diseases and the reduced need for trained personnel. NBM 200 offers a unique, breakthrough, non-invasive solution for accurate and quick Hb measurements. OrSense’s portable non-invasive device operates via a ring-shaped sensor that is fitted on the donor’s finger and applies pressure, temporarily occluding local blood flow. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the donor’s blood constituents, while greatly improving the donor’s comfort, eliminating infection risk, and providing the medical staff with accurate readings and immediate results.

About OrSense

OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense’s CE approved non-invasive hemoglobin monitor is available in 40 countries world-wide, and has been successfully installed in multiple environments including hospitals, physician offices, blood donation facilities, as well as used for various applications including public screening, women health and homecare. In addition, the Company’s FDA cleared NBM 200MP is a non-invasive blood oximetry monitor for use in hospitals. OrSense’s s products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. The Company’s CE approved glucose monitor was tested on over 450 diabetic subjects, showing performance similar to those of invasive glucose sensors. Investors in the Company include Israel Health Care Ventures and STAR Ventures. For additional information, please visit OrSense’s corporate website at www.orsense.com.

Press Contact:
Tsipi Haitovsky
Media Liaison
OrSense Ltd.
Tel: +972-52-598-9892
Email: tsipi.haitovsky@orsense.com

Nes Ziona, Israel, October 17, 2011 – OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, presented in an oral presentation at the American Society of Anesthesiologists (ASA) annual meeting in Chicago, results showing that its NBM 200MP, a non-invasive Hemoglobin (Hb) measurement system, detects hemorrhage accurately and within minutes. The sensitivity of the NBM 200MP was 96% compared to an invasive, “golden standard” measurement, and the non-invasive monitor detected hemorrhage in less than 4 minutes.

Hemorrhage is a significant cause of complications and death in various clinical situations. For example, post-partum hemorrhage is responsible for approximately 8% of direct pregnancy-related deaths in the industrialized countries, and 25% of maternal deaths in the developing world. Hemorrhagic shock is the second most frequent cause of death in trauma patients and is the leading cause of early in-hospital trauma deaths, and pre-operative hemorrhage leads to up to 4 times complications and death.
In hospitalized patients, who routinely receive liquid infusions, blood loss is accompanied by a rapid drop in Hb concentration, due to the dilution of the remaining blood with the infusion solution. Most trauma patients (up to 90%) also present with lower hemoglobin concentrations already upon arrival in the ER. Therefore, it is possible to monitor hemorrhage and blood loss by measuring Hb levels.

And yet, although it is a common, and often deadly complication, hemorrhage is often detected too late, due to lack of continuous methods for monitoring blood loss and Hb levels. The OrSense NBM 200MP, non-invasive, continuous Hemoglobin monitor offers, for the first time, the ability to monitor blood loss continuously and to detect hemorrhage within minutes.
Lior Maayan, CEO of OrSense, said, “The study presented at the ASA meeting substantiates the potential of the non-invasive NBM 200MP for accurate, continual, safe, and easy-to-use monitoring of Hb, in particular under technological-challenging, potentially life-threatening conditions such as hemorrhage. The study shows that our continuous Hb monitor offers, for the first time, the ability to detect hemorrhage within minutes, and with minimal effort and cost. The NBM 200MP can be instrumental in saving lives and reducing hospitalization complications and costs.”

Results of NBM 200MP hemoglobin clinical trial

The trial was conducted on 12 healthy volunteers in the VA Medical Center, Milwaukee, Wisconsin, and hemorrhage conditions were emulated by drawing 2 units of blood each subject. Subjects then received an infusion of isolyte fluid, which compensated for the missing blood volume and rapidly reduced the level of Hb. The removed 2 units of blood were then reinfused and increased the Hb back to normal.
Reference Hb values ranged from 8.4 g/dl to 15 g/dl and the reduction in Hb was between 2.6 g/dl and 3.8 g/dl. A reduction of 1 g/dL was taken to signify the onset of hemorrhage and was detected by the NBM 200MP in less than 4 minutes, with a sensitivity of 96%. For a total of 445 paired data points, the mean error between NBM 200MP readings and the arterial reference values was 0.29 g/dl. The standard deviation of error was 0.78 g/dl and the correlation 0.87. Use of the device did not cause any discomfort to subjects, was safe and well tolerated.

About NBM 200MP

Monitoring of Hb is essential for the detection of anemia and hemorrhage, and is widely used in the ICU, ER, operating and delivery rooms. The current measurement methods are invasive, painful, time consuming and labor intensive, and are inadequate for continuous Hb monitoring, often necessary during emergency situations, in order to detect hemorrhage. Non-invasive measurement of Hb has many advantages including the prevention of pain and potential transmission of infectious diseases, the reduced need for trained personnel and the freedom to take multiple measurements continuously. NBM 200MP offers a unique, breakthrough, non-invasive solution for accurate and quick Hb measurements.
OrSense’s portable non-invasive device operates via a ring-shaped sensor that is fitted on the subject’s finger and applies pressure, temporarily occluding local blood flow. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the donor’s blood constituents, while greatly improving the donor’s comfort, eliminating infection risk, and providing the medical staff with accurate readings and immediate results.

About OrSense

OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense’s CE approved non-invasive hemoglobin monitor is available in 40 countries world-wide, and has been successfully installed in multiple environments including hospitals, physician offices, blood donation facilities, as well as used for various applications including public screening, women health and homecare. In addition, the Company’s FDA cleared NBM 200MP is a non-invasive blood oximetry monitor for use in hospitals. OrSense’s s products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. The Company’s CE approved glucose monitor was tested on over 450 diabetic subjects, showing performance similar to those of invasive glucose sensors. Investors in the Company include Israel Health Care Ventures and STAR Ventures. For additional information, please visit OrSense’s corporate website at www.orsense.com.

Press Contact:

Tsipi Haitovsky
Media Liaison OrSense Ltd.
Tel: +972-52-598-9892
Email: tsipi.haitovsky@orsense.com

Nes Ziona, Israel, June 14, 2011 – On the World Blood Donors Day, OrSense Ltd., developer of monitors for non-invasive measurements of key blood parameters, presents its non-invasive hemoglobin (Hb) monitor, which holds potential to enhance recruitment and retention of blood donors.

Dr. Emma Castro, CEO of the Transfusion Center of the Spanish Red Cross in Madrid said, “A non-invasive system for the measurement of pre-donation Hb is eagerly awaited by both donors and staff. Our donors are very excited about the implementation of the new OrSense system and we are looking at it as a tool that will contribute to enlarge our blood donor community. Pricking the finger is experienced by our blood donors as the worst part of the process, thus the new apparatus will change their experience from a deterring to a pleasant one. Non-invasive Hb monitoring usher a new era for blood donation centers.”

Lior Ma’ayan, CEO of OrSense, said, “Our non-invasive Hb monitor, the first and only non-invasive Hb monitor available for use, increases donors and staff safety and allows for simple operation by the staff. All sides have to gain from non-invasive pre-donation Hb measurements: it dramatically increases donors’ comfort, and thus, we believe, will boost recruitment and retention of blood donors and encourage young, first time donors to donate blood.”

Dr. Castro will deliver an oral presentation discussing OrSense’s non-invasive monitor in the upcoming National Congress of SETS, the Spanish transfusion society, to be held in Malaga, Spain on June 15-17. In her talk, entitled “Evaluation of a new noninvasive system for the determination of Hb pre-donation,” Dr. Castro and her team show that OrSense’s non-invasive device achieves comparable results to those of invasive, commonly used techniques.

A similar conclusion was reached by Dr. R.N. Makroo from the Indraprastha Apollo Hospital in Delhi, India, who will be presenting his results at the Regional Conference of ISBT, the international society of blood transfusion, to be held June 18-22 in Lisbon,Portugal. Another study on the use of non-invasive Hb for anemia screening will be presented at ISBT by Aharon Weinstein from OrSense and Prof. A. Kornberg from the Department of Hematology and Blood Bank, Assaf Harofeh Medical Center, Israel.

OrSense non invasive Hb monitor performance was highlighted in a fourth study, during Euroanesthesia 2011 conference of the Europeans Society of anesthesia, held this week in Amsterdam, The Netherlands. The study, directed by Prof. P. Singer from the General ICU Rabin Medical Center, Israel and Aharon Weinstein from OrSense, shows that OrSense’s device is able to accurately track rapid changes in Hb levels, and maintains reliability even at very low Hb blood content. The publication focuses on hemorrhage that was emulated by hemodilution. OrSense’s non-invasive readings were compared to invasive, arterial blood samples. Reference Hb values ranged from 8.4 g/dl to 15 g/dl. The mean bias between NBM readings and the arterial reference values was 0.3 g/dl. The correlation was 0.9 and the standard deviation (SD) of error was 0.7 g/dl. The average personal SD was 0.5 g/dl.

About OrSense’s non-invasive hemoglobin monitor

OrSense’s portable non-invasive device operates via a ring-shaped sensor that is fitted on the donor’s finger and applies pressure, temporarily occluding local blood flow. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the donor’s blood constituents, while greatly improving the donor’s comfort, eliminating infection risk, and providing the medical staff with accurate readings and immediate results.

About OrSense

OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of oxygen saturation, hemoglobin, glucose and other blood parameters. The Company’s FDA cleared NBM 200MP is a non-invasive blood oximetry monitor for use in hospitals. OrSense’s non-invasive hemoglobin/hematocrit monitor was granted the CE approval and was tested on over 8,000 patients and donors at more than 20 sites in the U.S. and Europe. The Company’s products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. OrSense’s CE approved glucose monitor was tested on over 450 diabetic subjects, showing performance similar to those of invasive glucose sensors. Investors in the Company include Israel Health Care Ventures and STAR Ventures. For additional information, please visit OrSense’s corporate website at www.orsense.com .

Press Contact:

Tsipi Haitovsky
Media Liaison OrSense Ltd.
Tel: +972-52-598-9892
Email: tsipi.haitovsky@orsense.com

Nes Ziona, Israel, May 2, 2011 – OrSense Ltd., developer of monitors for non-invasive measurements of key blood parameters, announced today the closing of a U.S. $18 million financing led by Israel Healthcare Ventures (IHCV). Participating venture capital organizations include current investors: IHCV, STAR Ventures and Lewis Trust Private Equity division. The funds raised will be used to accelerate commercialization activities of the Company’s products for non-invasive monitoring of various blood parameters.

During 2010, OrSense has received FDA clearance for its non-invasive multi parameter monitor for continuous and spot measurement of normal and low signal oximetry for use in hospitals and outpatient sites. OrSense has also received CE approval for the first non-invasive spot and continuous monitor of hemoglobin for anemia screening and hemorrhage detection applications. This has enabled the Company to focus on the marketing and sales of non-invasive monitors of hemoglobin and oxygen saturation for which it has secured key clients and won tenders, while competing with current invasive and emerging non-invasive solutions. OrSense customers include blood donation facilities, hospital departments, public screening program and outpatient facilities. The Company’s products are based on its proprietary optical technology, Occlusion Spectroscopy, which eliminates the need for needle-stick blood tests, and overcomes key obstacles of competing approaches. OrSense’s devices were tested on 8000 subjects, in over 40 clinical trials in over 20 sites worldwide.

“We are extremely pleased to successfully raise this this new investment in OrSense which highlights the continuous support and confidence of our investors,” said Lior Ma’ayan, OrSense’s CEO. “Anemia is a key undiagnosed and untreated condition effecting around 2 billion people world-wide which may benefit from a painless, safe and easy to use screening solution. The funds secured will allow us to expand our commercialization efforts into additional point of care segments such as women’s health, public health programs and homecare. During 2011 we will expand our geographical reach beyond Europe to Asia Pacific, Africa and the Americas.”
Shimon Eckhouse, Ph.D., Chairman of OrSense’s Board of Directors, said, “”We believe that this additional investment will help us establish OrSense as the world leader in non-invasive monitoring of various blood parameters, promising a significant improvement to the quality of life of millions of people world-wide.”

About Occlusion Spectroscopy Technology

OrSense’s portable non-invasive devices operate via a ring-shaped sensor that is fitted on the patient’s finger and applies pressure, temporarily occluding local blood flow. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of patients’ and donors’ blood constituents, while greatly improving their comfort, eliminating infection risk, and providing the medical staff with accurate readings and immediate results.

About OrSense

OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurements of oxygen saturation, hemoglobin, glucose and other blood parameters. The Company’s FDA cleared NBM 200MP is a non-invasive blood oximetry monitor for use in hospitals. OrSense’s non-invasive hemoglobin/hematocrit monitor was granted the CE approval and was tested on over 8,000 patients and donors at more than 20 sites in the U.S. and Europe. The Company’s products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. OrSense’s CE approved glucose monitor was tested on over 450 diabetic subjects, showing performance similar to those of invasive glucose sensors. Investors in the Company include Israel Health Care Ventures and STAR Ventures. For additional information, please visit OrSense’s corporate website at www.orsense.com

Press Contact:

Tsipi Haitovsky
Media Liaison
OrSense Ltd.
Tel: +972-52-598-9892
Email: tsipi.haitovsky@orsense.com